申请人:Merck Sharp & Dohme Ltd.
公开号:US06476030B1
公开(公告)日:2002-11-05
Compounds according to Formula (I):
or a salt or prodrug thereof, have good affinity as ligands for the alpha2 and/or alpha3 subunit of the human GABAA receptor and are useful for treatment of disorders of the central nervous system, including anxiety and convulsions.
根据公式(I)合成的化合物或其盐或前药,具有良好的亲和力作为人类GABAA受体的α2和/或α3亚基的配体,并且对于治疗中枢神经系统疾病,包括焦虑和抽搐,是有用的。